Drugs for aids

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 2, 2010, Pages 147-161

  Ray, S ^a   Fatima, Z ^a   Saxena, A ^a  

^a AMITY UNIVERSITY   (India)

Author keywords

Aids; Anti hiv; Fusion inhibitor; Integrase inhibitor; Protease inhibitor; Reverse transcriptase inhibitor

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE MARROW DISEASE; BRAIN HEMORRHAGE; BREATHING DISORDER; BURN; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONVULSION; COUGHING; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG MECHANISM; DRUG METABOLISM; FATIGUE; FEVER; FLATULENCE; HAIR LOSS; HAND PAIN; HEADACHE; HEART INFARCTION; HEPATITIS; HEPATOMEGALY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INFECTION; INJECTION SITE REACTION; INSOMNIA; JAUNDICE; LACTIC ACIDOSIS; LIP DISEASE; LIPODYSTROPHY; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LOOSE FECES; MACULOPAPULAR RASH; MICTURITION; MOUTH PAIN; MOUTH ULCER; MYALGIA; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEPHROLITHIASIS; NERVOUSNESS; NONHUMAN; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRURITUS; RASH; SIDE EFFECT; SKIN COLOR; SKIN SENSATION; SORE THROAT; STOMACH PAIN; STRUCTURE ACTIVITY RELATION; SWEATING; TASTE DISORDER; TONGUE DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; VIVID DREAM; VOMITING; WEAKNESS; CHEMISTRY; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; HIV FUSION INHIBITORS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77954705120     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955710791185145     Document Type: Article

References (131)

1. Coffin, J.; Haase, A.; Levy, J.A.; Montagnier, L.; Oroszlan, S.; Teich, N.; Temin, H.; Toyoshima, K.; Varmus, H.; Vogt, P.; Weiss, R.A. What to call the AIDS virus? Nature, 1986, 321, 10.
2. AIDS epedimic update, UNAIDS, 2009.
3. Palella, F.J.Jr; Delaney, K.M; Moorman, A.C.; Loveless, M.O.; Fuhrer, J.; Satten, G.A.; Aschman, D.J.; Holmberg, S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N. Engl. J. Med., 1998, 338, 853-60.
4. Celum, C.L.; Coombs, R.W.; Lafferty, W.; Inui, T.S.; Louie, P.H.; Gates, C.A.; McCreedy, B.J.; Egan, R.; Grove, T.; Alexander, S., et al. Indeterminate human immuno deficiency virus type 1 western blot, seroconversion risk, specificity of supplemental tests and an algorithm for evaluation. J. Infect. Dis., 1991, 164, 656-64.
5. Centers for disease control and prevention. Revised guidelines for HIV counseling testing and referral MMWR. Recomn Rep 50 (RR- 19), 2001, 1-57.
6. Staszewski, S.; Morales-Ramirez, J.; Tashima, K.T. Rachlis, A.; Skiest, D.; Stanford, J.; Stryker, R.; Johnson, P.; Labriola, D.F.; Farina, D.; Manjon, D.J.; Ruiz, N.M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team. N. Engl. J. Med., 1999, 341, 1865-73.
7. Carr, A. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discov., 2003, 2, 624-34.
8. Carpenter, C.C.; Cooper, D.A.; Fischl, M.A.; Gatell, J.M.; Gazzard, B.G.; Hammer, S.M.; Hirsch, M.S.; Jacobsen, D.M.; Katzenstein, D.A.; Montaner, J.S.; Richman, D.D.; Saag, M.S.; Schechter, M.; Schooley, R.T.; Thompson, M.A.; Vella S.; Yeni, P.G.; Volberding, P.A., et al. Antiretroviral therapy in adults: updated recommendations of the international AIDS society-USA panel. JAMA, 2000, 283, 381-90.
9. Robbins, G.K.; De Gruttola, V.; Shafer, R.W.; Smeaton, L.M.; Snyder, S.W.; Pettinelli, C.; Dubé, M.P.; Fischl, M.A.; Pollard, R.B.; Delapenha, R.; Gedeon, L.; Van der Horst, C.; Murphy, R.L.; Becker, M.I.; D'Aquila, R.T.; Vella, S.; Merigan, T.C.; Hirsch, M.S., et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med., 2003, 349, 2293-303.
10. Shafer, R.W.; Smeaton, L.M.; Robbins, G.K.; Gruttola, V.D.; Snyder, S.W.; D'Aquila, R.T.; Johnson, V.A.; Morse, G.D.; Nokta, M.A.; Martinez, A.I.; Gripshover, B.M.; Kaul, P.; Haubrich, R.; Swingle, M.; McCarty, S.D.; Vella, S.; Hirsch, M.S.; Merigan, T.C. Comparison of four-drug regimens and pairs of sequential threedrug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med., 2003, 349, 2304-15.
11. Furman, P.A.; Fyfe, J.A.; St Clair, M.H.; Weinhold, K.; Rideout, J.L.; Freeman, G.A.; Nusinoff-Lehrman, S.; Bolognesi, D.P.; Broder, S.; Mitsuya, H. Phosphorylation of 3'-azido-3'- deoxythymidine & selective interaction of the 3'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA, 1986, 83, 8333-7.
12. Mitsuya, H.; Weinhold, K.J.; Furman, P.A.; St. Clair, M.H.; Lehrman, N.S.; Gallo, R.C.; Bloguesi, D.; Barry, D.W.; Broder, S. 3'-Azido-3'-deoxythymidine (BWA 509U): an antiviral agent that inhibits the inefectivity & cytopathic effect of human Tlymphotropic virus type III/ lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA, 1985, 82, 7096-100.
13. Goody, R.S.; Muller, B.; Restle, T. Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo. FEBS Lett., 1991, 291, 1-5.
14. Jiang, Y.Q.; Hao, E.J.; Li, W.; Yu, G.; Wang, W.; Chinere, J. Improved synthesis of zidovudine. Chin. J. Pharm., 2005, 36, 323.
15. Fischl, M.A.; Richman, D.D.; Grieco, M.H.; Gottlieb, M.S.; Volberding, P.A.; Laskin, O.L.; Leedom, J.M.; Groopman, J.E.; Mildvan, D.; Hirsch, M.S., et al. The efficacy of azidothimidine (AZT) in the treatment of patients with AIDS and AIDS related complex. A double blind placebo-controlled trial. N. Engl. J. Med., 1987, 317, 185-91.
16. Connor, E.; Sperling, R.; Gelber, R.; Kiselev, P.; Scott, G.; O'Sullivan, M.J.; VanDyke, R.; Bey, M.; Shearer, W.; Jacobson, R.L.; Jimenez, E.; O'Neill, E.; Bazin, B.; Delfraissy, J.F.; Culnane, M.; Coombs, R.; Elkins, M.; Moye, J.; Stratton, P.; Balsley, J., et al. Reduction of maternal infant transmission of human immunodeficiency virus type-I with ziduvudine treatment. Pediatric AIDS clinical trials group protocol 076 study group. N. Engl. J. Med., 1994, 331, 1173-80.
17. Ferman, P.; Fyfe, J.; St Clair, M.; Winhold, K.; Freeman, G.A.; Lehrman, S.N.; Bolognesi, D.P.; Broder, S.; Mitsuya H., et al. Phosphorylation of 3'-azido-3-deoxythimidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA, 1986, 83, 8333-7.
18. Robbins, M.J. Antiretroviral therapy for hepatitis B with 2', 3'- dideoxypurine nucleoside. U.S. Patient number 5039667, dt Aug 13, 1991.
19. Yarchoan, R.; Mitsura, H.; Thomas, R.V.; Pluda, J.M.; Hartman, N.R.; Perno, C.F.; Marczyk, K.S.; Allain, J.P.; DG Johns, D.G.; Broder, S. In vivo activity against HIV and favourable toxicity profile of 2', 3'- dideoxyinosine. Science, 1989, 245, 412-5.
20. Shelton, M.J.; O' Donnell, A.M.; Morse, G.D., Zalcitabine. Ann. Pharmacother., 1993, 27, 480-9.
21. Mitsuya H.; Yarchaon, R.; Broder, S. Molecular targets for AIDS therapy. Science, 1990, 249, 1533-44.
22. Moyle, G.J. Use of viral resistance patterns to antiretroviral drugs in optimizing selection of drug combination and sequences. Drugs, 1996, 52, 168-85.
23. Horwitz, J.P. Nucleside IX. The formation of 2', 3'-unsaturated pyrimidine nucleoside via a novel beta elimination reaction. J. Org. Chem., 1996, 31, 205-11.
24. Liu, S.L.; Ye, F.; Chen, Y.; Shen, X.X. Synthesis of Stavudine. Chinese J. Pharma., 2006, 37, 510-2.
25. Hurst, M.; Noble, S. Stavudine: a update of its use in the treatment of HIV infection. Drugs, 1999, 58, 919-49.
26. Skowron, G. Biological effects and safety of stavudine: overview of phase I clinical trials. J. Infec. Dis., 1995, 171, S113-7.
27. Goodyear, M.D.; Hill, M.L.; West, J.P.; Whitehead, A.J. Practical enantioselective synthesis of lamivudine (3TC) via a dynamic kinetic resolution. Tet. Lett., 2005, 46, 8535-8.
28. Sorbera, L.A.; Castaner, J.; Bayes, M. A.CH-126443: Anti-HBV anti-HIV. Drugs Future, 2002, 27, 1131-40.
29. Gharpure, M.M.; Bhaal, B.M.; Rane, D.R.; Barde, A.R.; Zope, U.R.; Mehta, S.R. Industrial process for the manufacture of lamivudine. Pat. Application no. 1570/MUM/2005. Published 07/13/2007.
30. Kwon, S.Y.; Choe, W.H.; Lee, C.H.; Yeon, J.E.; Byun, K.S.; Rapid re-emergence of YMDD mutation of HBV with hepatic decompensation after lamivudine re-treatment. World J. Gastroenterol, 2008, 14, 4416-9.
31. Graul, A.; Leeson, P.A.; Castaner, J. Abacavir sulfate. Drugs Future, 1998, 23, 1155-67.
32. Rossia, A.; Vecchio, E.; Pizzocaro, R.; Bedeschi, A. Process for the preparation of abacavir. European Pat EP 1857458. Publication date: 11/21/2007.
33. Chapman, T.M.; McGavin, J.K.; Noble, S. Tenofovir Disoproxil Fumarate: AIDS drug profile. Drugs, 2003, 6, 1597-608.
34. Arimilli, M.; Kim, C.; Bischofberger, N. Synthesis, In vitroevaluatio, and oral bioavailability of 9-[2- (phosphonomethoxy)propyladenine(PMPA) prodrugs. Antimicrob. Agents Chemother., 1997, 8, 557-64.
35. Deeks, S.G.; Barditch- Crovo, P.; Lietman, P.S.; Hwang, F.; Cundy, K.C.; Rooney, J.F.; Hellmann, N.S.; Safrin, S. Kahn, J.O. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy) propyladenine, a novel anti-human immunodeficiency virus(HIV) therapy, in HIV infected adults. Antimicrob. Agents Chemother., 1998, 42, 2380-4.
36. Lee, W.A.; He, G.X.; Eisenberg, E.; Cihlar, T.; Swaminathan, S.; Mulato, A.; Cundy, K.C. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor Tenofovir leads to a preferential distribution and accumulation in lymphatic tissue. Antimicrob. Agents Chemother., 2005, 49, 1898-906.
37. Pauwels, R.; Balzarini, J.; Schols, D.; Baba, M.; Desmyter, J.; Rosenberg, I.; Holy, A.; Clercq, E.D. Phosphonyl methoxymethyl purine derivatives, a new class of ti- human immunodeficiency virus agent. Antimicrob. Agents Chemother., 1988, 32, 1025-30.
38. Meng, J.F.; Wu, X.S.; Cen, J.D. Synthesis of emtricitabine. Chinese J. Pharma., 2005, 36, 589-90.
39. Margot, N.A.; Waters, J.M.; Miller, M.D. In vitro human imunodeficieny virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob. Agents Chemothe., 2006, 50, 4087-95.
40. Mehellou, Y.; De Clercq, E. The current status of HIV chemotherapy. IB Scientific J. Sci., 2007, 2, 44-56.
41. Sluis-Cremer, N.; Temiz, N.A.; Bahar, I. Conformational changes in HIV-1 reverse transcriptase induced by non-nucleoside reverse transcriptase inhibitor binding. Curr. HIV Res., 2004, 2, 323-32.
42. Rivero, A.; Mira, J.A.; Pineda, J.A. Liver toxicity induced by NNRTIs. J. Antimicrob. Chemother., 2007, 59, 342-6.
43. Hajos, G.; Riedle, Z.; Molnar J.; Szabo, D. Non nucleoside reverse transcriptase inhibitors. Drug Future, 2000, 25, 47-62.
44. Montaner, J.S.G.; Reiss, P.; Cooper, D.; Vella, S.; Harris, M.; Conway, B.; Wainberg, M.A.; Smith, D.; Robinson, P.; Hall, D.; Myers, M.; Lange, J.M.A. A randomized double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV infected patients. The INCAS trial. JAMA, 1998, 279, 930-7.
45. Ren, J.; Bird, L.E.; Chamberlain, P.P.; Stewart-Jones, G.B.; Stuart, D. I.; Stammers, D.K. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA, 2002, 99, 14410-5.
46. Guay, L.A.; Musoke, P.; Flening, T.; Bagenda, D.; Allen, M.; Nakabiito, C.; Sherman, J.; Bakaki, P.; Ducar, C.; Deseyve, M.; Emel, L.; Mirochnick, M.; Fowler, M.G.; Mofenson, L.; Miotti, P.; Dransfield, K.; Bray, D.; Mmiro, F.; Jackson, J.B. Intrapartum and neonatal single dose nevirapine compared with zidovudine for prevention of mother to chile transmission of HIV-1 in Kampala, Uganda: HIV NET 012 randomized trial. Lancet, 1999, 354, 795-802.
47. Johnson, J.A.; Li, J.F.; Morris, L.; Martinson, N.; Gray, G.; McIntyre, J.; Heneine, W. Resistance HIV-1 after intrapartum administration of single dose nevirapine is substantially under estimated. J. Infect. Dis., 2005, 192, 16-23.
48. Eron, J.; McKinley, G.; Lecrerq, P.; Nieto, L.; Wathen, L.; Pietrantoni, C.; Greenwald, C.; Conklin, M.; Paxton, L.; Freimuth, W. Potent anti viral activity using delavirdine and reduced-dose indinavir combination therapies: a 48 week analysis. Conference on retroviruses and opportunistic infections. San Franc.Calif. Jan 30- Feb 2, 2000.
49. Graul, A.; Rabasseda, X.; Castaner, J. Efavirenz. Drugs Future, 1998, 23, 133-41.
50. Albrigh, A.V.; Erickson -Vitanen, S.; O'Connov, M.; Frank, I.; Rayner, M.M.; Gonzalez-Scarano. Efavirez is a potent nonnucleoside reverse transcriptase inhibitor of HIV type I. Replication in microglia in vitro. AIDS Res. Hum. Retroviruses, 2000, 16, 1527-37.
51. Cespedes, H.S.; Aberg, J.A. Neuropsychiatry complications of antiretroviral therapy. Drug Safety, 2006, 29, 865-74.
52. Lochet, P.; Peyriere, H.; Lotthe, A.; Mauboussiz, J.M.; Dclmas, B.; Reynes, J. Long-term assessment of neuropsychiatry adverse reactions associated with efavirenz. HIV Med., 2003, 4, 62-6.
53. Blanch, J.; Corbella, B.; Garcia, F.; Parellada, E.; Gatell, J.M. Manic syndrome associated with Efavirenz overdose. Clin. Infect. Dis., 2001, 33, 270-1.
54. Davies, S.; L. Castaner, J.; Silvestres, J.S.; Bayes, M. Etravirine. Drugs Future, 2005, 30, 462-8.
55. Etravirine: R165335, TMC 125. Drugs R D., 2006, 7, 367-73.
56. Das, K.; Clark, A.D.; Jr. Lewi, P.J.; Heeres, J.; De Jonge, M.R.; Koymans, L.M.; Vinkers, H.M.; Daeyaert, F.; Ludovici, D.W.; Kukla, M.J.; De Corte, B.; Kavash, R.W.; Ho, C.Y.; Ye, H.; Lichtenstein, M.A.; Andries, K.; Pauwels, R.; De Béthune, M.P.; Boyer, P.L.; Clark, P.; Hughes, S.H.; Janssen, P.A.; Arnold, E. Roles of conformational and positional adaptability in structurebased design of TMC 125-R165335 (etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug resistant HIV-1 variants. J. Med. Chem., 2004, 47, 2550-60.
57. Stelbrink, H.J. Antiviral drugs in the treatment of AIDS: what is in the pipe line. Eur. J. Med. Res., 2007, 12, 483-95.
58. Sahlberg, C.; Zhou, X.X. Development of non-nucleoside reverse transcriptase inhibitors for anti-HIV therapy. Anti-Infective Agents Med. Chem., 2008, 7, 101-17.
59. Das, K.; Clark, A.D. Jr.; Lewi, P.J.; Heeres, J.; De Jonge, M.R.; Koymans, L.M.; Vinkers, H.M.; Daeyaert, F.; Ludovici, D.W.; Kukla, M.J.; De Corte, B.; Kavash, R.W.; Ho, C.Y.; Ye, H.; Lichtenstein, M.A.; Andries, K.; Pauwels, R.; De Béthune, M.P.; Boyer, P.L.; Clark, P.; Hughes, S.H.; Janssen, P.A.; Arnold, E. Roles of conformational and positional adaptability in structurebased design of TMC125-R165335 (Etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem., 2004, 47, 2550-60.
60. Dueweke, T.J.; Kezdy, F.J.; Waszak, G.A.; Deibel, M.R. Jr.; Tarpley, W.G. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase J. Biol. Chem., 1992, 267, 27-30.
61. Romero, D. L.; Morge, R. A.; Genin, M. J.; Biles, C.; Busso, M.; Resnick, L.; Althaus, I. W.; Reusser, F.; Thomas, R. C.; Tarpley, W. G. Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogs and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl) carbony l]-4-[3-[(1 methylethyl) amino] pyridinyl] piperazine monomethane sulfonate (U-90152S), a second-generation clinical candidate J. Med. Chem., 1993, 36, 1505-8.
62. Dueweke, T.J.; Poppe, S.M.; Romero, D.L., et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agent. Chemother., 1993, 37, 1127-31
63. Genin, M. J.; Poel, T. J.; Yagi, Y.; Biles, C.; Althaus, I.; Keiser, B.J.; Kopta, L.A.; Friis, J.M.; Reusser, F.; Adams, W.J.; Olmsted, R.A.; Voorman, R.L.; Thomas, R.C.; Romero, D.L. Synthesis and bioactivity of novel bis (heteroaryl) piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships and increased metabolic stability of novel substituted pyridine analogs. J. Med. Chem., 1996, 39, 5267-75
64. Romero, D. L.; Olmsted, R.L.; Poel, T.J.; Morge, R.A.; Biles, C.; Keiser, B.J.; Kopta, L.A.; Friis, J.M.; Hosley, J.D.; Stefanski, K.J.; Wishka, D.G.; Evans, D.B.; Morris, J.; Stehle, R.G.; Sharma, S.K.; Yagi, Y.; Voorman, R.L.; Adams, W.J.; Tarpley, W.G.; Thomas, R.C. Targeting delaverdine/atevirdine resistant HIV-1: Identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors. J. Med. Chem., 1996, 39, 3769-89.
65. Romero, D.L.; Morge, R.A.; Biles, C.; Berrios-Pena, N.; May, P.D.; Palmer, J.R.; Johnson, P.D.; Smith, H.W.; Busso, M., et al. Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem., 1994, 37, 999-1014.
66. Karl D. Hargrave; John R. Proudfoot; Karl G. Grozinger; Ernest Cullen, Suresh R. Kapadia; Usha R. Patel; Victor U. Fuchs; Scott C. Mauldin; Jana Vitous. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. tricyclic pyridobenzo- and dipyridodiazepinones. J. Med. Chem., 1991, 34, 2231-41.
67. Proudfoot, J. R.; Hargrave, K. D.; Kapadia, S. R.; Patel, U. R.; Grozinger, K.G.; McNeil, D. W.; Cullen, E.; Cardozo, M; Tong, L. Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes. J. Med. Chem., 1995, 38, 4830-8.
68. Patel, M.; McHugh, R.; Cordova, B.; Klabe, R.; Erickson- Vitanen, S.; Trainor, G.; Ko, S. Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA) Bioorg Med Chem. Lett., 1999, 9, 3221-4.
69. Patel, M.; Ko, S.; McHugh, R.; Markwalder, J.; Srivastava, A.; Cordova, B.C.; Klabe, R.M.; Erickson-Viitanen, S.; Trainor, G.L.; Seitz, S.P. Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 1999, 9, 2805-10.
70. Brik, A.; Wong, C.H. HIV-1 protease: mechanism and drug discovery. Org. Biomol. Chem., 2003, 1, 5-14.
71. Flexner, C. HIV protease inhibitors. New. Eng. J. Med., 1998, 338, 1281-93.
72. Carr, A.; Samaras, K.; Chisholm, D.J.; Coper, D.A. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyper lipedaemia and insulin resistance. Lancet, 1998, 351, 1881-3.
73. Henry, K., et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998, 351, 1328.
74. David, Y.H. HIV protease inhibitors and atherosclerosis.J. Clin. Invest., 2003, 111, 317-8.
75. Wacher, V.J.; Silverman, J.A.; Zhang, Y.; Benet, L.Z. Role of Pglycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci., 1998, 87, 1322-30.
76. Parkes, KEB., et al. Studies towards the large scale synthesis of the HIV proteinase inhibitors RO-31-8959. J. Org. Chem., 1994, 59, 3656-64.
77. Yang, O.G.; He, X.C.; Lei, L.J.; Zhou, O.T.; Bai, D.I. An improved synthetic method of saquinavir. Chemical Res. Chinese Universities, 2006, 22, 51-5.
78. Dragsted, U.B.; Gerstoft, J.; Pedersen, C., et al. Randomized trial to evaluate indinavir (ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type-I infected patients. The Max Cunin 1 Trial. J. Infect Dis., 2003, 188, 635-42.
79. Inventor: Bellani, P.; Frigerio, M.; Castoldi, P. Process for the synthesis of ritonavir. US patent 6407252 dated June 18, 2002 Pat. No. WO/2001/02/603, dt. 29.03.2001.
80. Zeldin, R.K.; Petrusche, R.A. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIVinfected patients. J. Antimicrob. Chemother., 2004, 53, 4-9.
81. Kempf, D.J.; Marsh, K.C.; Kumar, G., et al. Pharmacokinetic enhancement of the human imunodeficiency virus & protease by co-administration with retonavir. Antimicrob.Agents Chemother., 1997, 41, 654-60.
82. Merry, C.; Barry, M.G.; Mulcahy, F.; Ryan, M.; Heavey, J.; Tija, J.F.; Gibbons, S.E.; Breckenridge, A.M.; Back, D.J. Saquinavir, pharmacokinetics alone and in combination with ritonavir in HIV-infected patients [FAST TRACK] AIDS, 1997, 11, 29-33.
83. Sharma, B.; Singh, N.; Singh, M.; Jaggi, A.S. Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia. Pharmaco. Biochem Behav., 2008, 89, 535-45.
84. Askin, D. The synthesis of indinavir and other clinically useful HIV-I protease inhibitors. Curr. Opin. Drug Disc. Dev., 1998, 1, 338-48.
85. Cheng, Y.; Zhijian, Lu; Chapman, K. T.; Tata, J. R. Solid Phase Synthesis of Indinavir and Its Analogues. J. Comb. Chem., 2000, 2, 445-6.
86. Albizati, K.F.; Babu, S.; Birchper, A.; Busse, J. K.; Fugett, M.; Grubbs, A.; Haddach, A.; Pagan, M.; Potts, B.; Remarchuk, T.; Rieger, D.; Rodriguez, R.; Shanley, J.; Szendroi, R.; Tibbetts, T.; Whitten, K.; Borer, B.C.; et al. A synthesis of the HIV-protease inhibitor nelfinavir from D-tartaric acid. Tet. Lett., 2001, 42, 6481-5.
87. Kaldor, S.W.; Kalish, V.J.; Davies2nd, J.F.; Shetty, B.V.; Fritz, J.E.; Appelt, K.; Burgess, J.A.; Campanale, K.M.; Chirgadze, N.Y.; Clawson, D.K.; Dressman, B.A.; Hatch, S.D.; Khalil, D.A.; Kosa, M.B.; Lubbehusen, P.P.; Muesing, M.A.; Patick, A.K.; Reich, S.H.; Su, K.S.; Tatlock, J.H. Viracept (nefinavir mesylate, AG 1343): A potent orally bioavailable inhibitor of HIV-1 protease. J. Med Chem., 1997, 40, 3979-85.
88. Sriram, D.; Yogeeswari, P.; Dinakaran, M.; Sowmya, M. Synthesis, anti HIV & anti tubercular activities of nelfinavir diester derivative Kaletra (lopinavir/ ritonavir). Biomedicine & Pharmacotherapy, 2008, 62, 1-5.
89. Honda, Y.; Katayama, M.; Kajima, M.; Suzuki, T.; Kishibata, N.; Izawa, K. Org. Biol. Chem., 2004, 2, 2061-70.
90. Stoner, E.J.; Cooper, A.J.; Dickman, D.A.; Kolaczkowski, L.; Lallaman, J.E.; Liu, J.H.; Oliver-Shaffer, P.A.; Patel, K.M.; Paterson, J.B.; Plata, D.J.; Riley, D.A.; Sham, H.L.; Stengel, P.J.; Tien, J.H. Synthesis of HIV protease inhibitor ABT-378 (Lopinavir). Org. Proc. Res. Dev., 2000, 4, 264-9.
91. Love, R.A.; Parge, H.E.; Wickersham, J.A., et al. The conformation of hepatitis C virus NS3 protinase with and without NS4A: a structural basis for the activation of the enzyme by its cofactor. Clin. Diagn. Virol., 1998, 10, 151-6.
92. Hong-Brown, L.Q.; Bron, R.; Huber, D.; Lany, C.H. Lopinavir impairs protein synthesis and induces eEF2 phosphorylation via the activation of AMP-activated protein kinase. J. Cellular. Biochem., 2008, 105, 814-23.
93. Magnum, E.M.; Graham, K.K. Lopinavir-Ritonavir: a new protease inhibitor. Pharmacotherapy, 2001, 21, 1352-63.
94. Corbett, A.H.; Lim, M.L.; Kashuba, A.D. Kaletra (lopinavir/ritonavir). Ann. Pharmacothe., 2002, 36, 1193-203.
95. Kikuchi, Y.; Genka, I.; Ishizaki, A.; Sunagawa, K.; Yasuoka, A.; Oka, S. Serious bradyarrhythmia that was possibly induced by lopinavir-ritonavir in 2 patients with acquired immunodeficiency syndrome. Clin. Infect. Dis., 2002, 35, 488-90.
96. Eron, J. Jr.; Yeni, P.; Gathe, J. Jr. DeJesus, E.; Staszewski, S.; Lackey, P.; Katlama, C.; Young, B.; Yau, L.; Sutherland-Phillips, D.; Wannamaker, P.; Vavro, C.; Patel, L.; Yeo, J.; Shaefer, M. The KLEAN Study of fosamprenavir-ritonavir versus lopinavirritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infections are 48 weeks: a randomized noninferiority trial. Lanct, 2006, 368, 476-82.
97. Gathe, J.C Jr.; Ive, P.; Wood, R.; Schurmann, D.; Bellos, N.C.; De Jesus, E.; Gladysz, A.; Garris, C.; Yeo, J. SOLO:48 week efficacy and safety comparison of once daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naïve HIV-1 infected patients. AIDS, 2004, 18, 1529-37.
98. Witherell, G. BMS-232632 Novartis/Bristol-Myers Squibb. Curr. Opin. Invest. Drugs, 2001, 2, 340-7.
99. Pyrteo, P. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res., 2007, 67, 10920-8.
100. Turner, S.R.; Strohbach, J.W.; Tommasi, R.A.; Aristoff, P.A.; Johnson, P.D.; Skulnick, H.I.; Dolak, L.A.; Seest, E.P.; Tomich, P.K.; Bohanon, M.J.; Horng, M.M.; Lynn, J.C.; Chong, K.T.; Hinshaw, R.R.; Watenpaugh, K.D.; Janakiraman, M.N.; Thaisrivongs, S., et al. Tipranavir (PNU-140690). A potent, orally bioavailable, nonpeptidic HIV protease inhibitor of the 5, 6- dihydro-4-hydroxy -2-pyrone sulfonamide class. J. Med. Chem., 1998, 41, 3467-76.
101. Thompson, L.A.; Tebben, A.J. Pharmacokinetics and design of aspartyl protease inhibitor. Annual Reports in Medicinal Chemistry, 2001, 36, 247-56.
102. McCallister, S.; Valdez, H.; Curry, K.; MacGregor, T.; Borin, M.; Freimuth, W.; Wang, Y.Y.; Mayers, D.L. A 14 day dose response study of the efficacy, safety and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naïve-HIV-1infected patients - JAIDS, 2004, 35, 376-82.
103. Graff, J.; Von Hentig, N.; Kuczka, K.; Angiom, C.; Gute, P.; Klauke, S.; Babacan, E.; Harder, S. Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J. Antimicrob. Chemother., 2008, 61, 394-9.
104. Ghosh, A.K.; Dawson, Z.L.; Mitsua, H. Darunavir, a conceptually new HIV-1 protease inhibitor for the reatment of drug-resistant HIV. Bioorg. Med. Chem., 2007, 15, 7576-80.
105. Clotet, B.; Bellos, N.; Molina, J-M. Cooper, D.; Goffard, J.C.; Lazzarin, A.; Wöhrmann, A.; Katlama, C.; Wilkin, T.; Haubrich, R.; Cohen, C.; Farthing, C.; Jayaweera, D.; Markowitz, M.; Ruane, P.; Spinosa-Guzman, S.; Lefebvre, E. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER-1 and 2: a pooled subgroup analysis of data from two randomized trials. Lancet, 2007, 369, 1169-78.
106. Lu, Z.; Ragharan, S.; Bohn, J. Charest, M.; Mark W., Stahlhut, M.W.; Rutkowski, C.A.; Simcoe, A.L.; Olsen, D.B.; Schleif, W.A.; Carella, A.; Gabryelski, L.; Jin, L.; Lin, J.H.; Emini, E.; Chapman K.; R. Tata, J.R. Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus. Bioorg. Med. Chem. Lett., 2003, 13, 1821-4.
107. Nagaranjan, S.R.; Crescenzo, G.A.; German, D. P.; Lu, H.F.; Sikorski, J.A.; Walker, J.L.; Mcdonald, J.J.; Houseman K.A.; Kocan, G.P.; Kishore, N.; Mehta, P.P.; Funkes-shippy, C.L.; Blystone, L. Discovery of novel benzothiazolesulfonamides as potent inhibitors of HIV-1 protease. Bioorg. Med. Chem., 2003, 11, 4769-77.
108. Bhat, M.A.; Siddiqui, N.; Khan, S.A.; Ahmad, M.; Non-peptide protease inhibitors as novel anti HIV agents. IJPS, 2006, 68, 549-55.
109. Bray, B.L. Large scale manufacture of peptide therapeutics by chemical synthesis. Nature Rev. Drug Disc., 2003, 2, 587-93.
110. Earl, P.L.; Doms, R.W.; Moss, B. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci., USA, 1990, 87, 648-52.
111. Lasky, L.A.; Nakamura, G.; Smith, D.H., et al. Delineation of a region of the human immunodeficiency virus type-I gp 120 glycoprotein critical for interaction with the CD4 receptor. Cell, 1987, 50, 975-85.
112. Kliger, Y.; Gallo, Sa.; Peisajovich, S.G., et al. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post- lipid mixing stage. J. Biological. Chem., 2001, 276, 1391-7.
113. Lalezari, J.P.; Eron, J.J.; Carlson, M., et al. A phase-II clinical study of the long term safety and antiviral activity of enfuvirtidebased antiretroviral therapy. AIDS, 2003, II, 641-8.
114. Kilby, J.M.; Hopkins, S.; Venetta, T.M.; DiMassimo, B.; Cloud, G.A.; Lee, J.Y.; Alldredge, L.; Hunter, E.; Lambert, D.; Bolognesi, D.; Matthews, T.; Johnson, M.R.; Nowak, M.A.; Shaw, G.M.; Saag, M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp 41-mediated virus entry. Nat. Med., 1998, 4, 1302-7.
115. Lalezaris, J.P., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug - resistant HIV infection in North and South America. New Eng. J. Med., 2003, 348, 2175-85.
116. Greenberg, M.L; Cammack, N. Review: Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother., 2004, 54, 333-40.
117. Kuritzkeys, D.; Kar, S.; Kirkpatrik, P. Maraviroc. Nat. Rev. Drug Discov., 2008, 7, 15-6.
118. Rosario, M.C.; Poland, B.; Sullivan J.; Westby, M.; VanduRyst, E. A pharmacokinetic - pharmacodynamic model to optimize the phase II, a development programme of maraviroc. JAIDS, 2006, 42, 183-91.
119. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Pvine, B.; Macartney, M.; Mori, J.; Rickett G.; Smity - Burchnell, C.; Napier, C.; Webster, R.; Amour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small molecule inhibitor of chemokine receptor CCR5 with broad - spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother., 2005, 49, 4721-32.
120. Fatkenhener, G.; Pozniak, A.L.; Johnson, M.A.; Plettenber, A.; Sfazzewski, S.; Hoepelman, A.L.; Saag, M.S.; Goebel, F.D.; Rockstroh, J.K.; Dezube, B.J.; Jenkins, T.M.; Medhurst, C.; Sullivan, J.F.; Ridgway, C.; Abel, S.; James, I.T.; Youle, M.; VandorRyst, E. Efficiency of short-term monotherapy with marviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med., 2005, 11, 1170-2.
121. Wood, A.; Armour, D. The discovery of the CCR5 receptor antagonist, UK-427, 857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem., 2005, 43, 239-71.
122. Walker, D.K.; Abel, S.; Comby, P.; Muirhead, G.J.; Nedderman, A.N.; Smith, D.A. Species differences in the disposition of the CCR5 antagonist, UK-427, 857, a new potential treatment for UK- 427, 857, a new potential treatment for HIV. Drug Metabolism and Disposition: The Biological Fate of Chemical, 2005, 33, 587-95.
123. Price, D.A.; Gayton, S.; Selby, M.D.; Ahman, J.; Haycock- Lewandowski, S.; Stammen, B.L; Warren, A.; Stinchuri Initial synthesis of UK-427, 857 (Maraviroc). Tet. Lett., 2005, 46, 5005-7.
124. Savarimo, A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert. Opin. Investig. Drugs, 2006, 15, 1507-1.
125. Espeseth, A.S.; Felock, P.; Wolfe, A., et al. HIV-1 integrase inhibitors that compete with target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. USA, 2000, 97, 11244-9.
126. Steigbigel, R.T.; Cooper, D.A.; Kumar, P.N.; Eron, J.E., et al. Raltegravir with Optimized Background Therapy for resistant HIV- 1 infection. N. Engl. J. Med., 2008, 359, 339-54.
127. Kassahun, K.; Mc Intosh, I.; Cui, D., et al. Metabolism and disposition in humans of raltegravir (MK - 0518), and anti-AIDS drug targeting the Human Immunodeficiency Virus-1 integrase enzyme. Drug Metabolism and Disposition Fast Forward, 2007, DOI:10.1124/dmd.10T.016196. DMD (2007) # 16196 1.
128. Hazula, D.J.; Felock, P.; Witmer, M., et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science, 2000, 287, 646-50.
129. Hazuda, D.J.; Young, S.D.; Guare, J.P. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science, 2004, 305, 528-32.
130. Markowitz, M.; Morals-Ramirez, J.O.; Nguyen, B.Y. Antiretroviral activity, pharmacokinetics, and tolerability of MK-o518, a novel inhibitor of HIV-1 integrase, dosed as mono therapy for 10 days in treatment - naïve HIV-1 infected individuals. JAIDS, 2006, 43, 509-15.
131. Cotelle, P. Patented HIV-1 integrase inhibitors (1998-2005). Recent Patents on Ant-Infective Drug Discov., 2006, 1, 1-15.